{"id":"W2531125083","doi":"10.1158/1078-0432.ccr-15-3069","title":"Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cégep de Saint-Laurent; Hôpital Notre-Dame","funders":"AbbVie","keywords":"Veliparib; Carboplatin; Medicine; Placebo; PARP inhibitor; Internal medicine; Lung cancer; Paclitaxel; Clinical endpoint; Oncology; Urology; Cancer; Surgery; Chemotherapy; Randomized controlled trial; Pathology; Cisplatin; Biology; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003047611,0.0021901,0.00477299,0.0007017784,0.0007041228,0.001615866,0.001642867,0.002105751,0.007480794],"category_scores_gemma":[0.002632761,0.001205574,0.001679394,0.0007771201,0.001884609,0.001276692,0.0005452806,0.004428519,0.001466377],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001054101,"about_ca_system_score_gemma":0.001953125,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009026999,"about_ca_topic_score_gemma":0.001834437,"domain_scores_codex":[0.9987656,0.0007133312,0.00007494403,0.000212713,0.00008979733,0.0001437767],"domain_scores_gemma":[0.998421,0.000393621,0.0003553746,0.0001482729,0.0001323243,0.0005494636],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9819043,0.009999632,0.0002103579,0.0003387997,0.0005409607,0.00002413044,0.00002503978,0.0001752812,0.001958787,0.00005435839,0.0004381347,0.004330206],"study_design_scores_gemma":[0.9635938,0.03529358,0.0003374781,0.00000975317,0.0001426758,0.00001077218,0.000007265686,0.0001606799,0.0001570429,0.00004842269,0.0002329599,0.000005621184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9651446,0.005007581,0.001766016,0.001130787,0.001571613,0.02015101,0.002112979,0.0002864973,0.002828895],"genre_scores_gemma":[0.9641255,0.003118621,0.003364751,0.001806799,0.00113526,0.02044841,0.001724568,0.00005312081,0.004223004],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007480794,"threshold_uncertainty_score":0.02502578,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1396071167747304,"score_gpt":0.5230751276709501,"score_spread":0.3834680108962196,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}